DLL3 goes trispecific
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
ASCO 2025 – Amgen gets one over on Zai Lab
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
Amgen takes Imdelltra front line
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
AACR 2025 preview – new preclincal approaches abound
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
Zai Lab looks towards an accelerated pathway
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
